7 May 2025
The Paediatric Society of New Zealand is calling for Pharmac to fund nirsevimab (Beyfortus) to help protect babies from respiratory syncytial virus (RSV) — one of the leading causes of infant hospitalisations in Aotearoa.
Nirsevimab is a long-acting antibody that offers protection against RSV with a single injection. It’s already approved and in use across Australia, Europe, Canada, and the United States.
In a submission to Pharmac, the Society highlights that:
-
RSV hits Māori, Pacific, and rural communities hardest
-
Nirsevimab can significantly reduce hospitalisations
-
One dose offers season-long protection, making it easier for whānau to access
-
Funding this treatment supports more equitable care and aligns with Pae Ora and Te Tiriti o Waitangi
PSNZ is urging swift action and stands ready to support the rollout of this important preventive treatment.
Read the full submission below 👇